Clinical Utility of Including Circulating Tumor DNA (ctDNA) Monitoring in Standard-of-Care (SOC) Colorectal Cancer (CRC) Surveillance

home / between-the-lines / clinical-utility-of-including-circulating-tumor-dna-ctdna-monitoring-in-standard-of-care-soc

Experts discuss how multidisciplinary care, pathology review, surgical quality, and circulating tumor DNA (ctDNA) testing together personalize colorectal cancer surveillance and treatment, improving early detection, guiding therapy decisions, reducing patient anxiety, and enhancing long-term outcomes across diverse clinical settings.

The Oncology Surgeon’s Role in Postoperative Surveillance Following CRC Resection

EP. 1: The Oncology Surgeon’s Role in Postoperative Surveillance Following CRC Resection

John H. Strickler, MD;Robert C.G. Martin II, MD, PhD, FACS
August 20th 2025

Experts discuss how postsurgical surveillance for colorectal cancer varies by setting, with multidisciplinary teams leading coordinated care in academic centers, whereas surgeons in rural or resource-limited areas often take on expanded roles to ensure follow-up and monitoring are not compromised.

Communicating the Risk of Disease Relapse to the Patient After Curative CRC Resection

EP. 2: Communicating the Risk of Disease Relapse to the Patient After Curative CRC Resection

John H. Strickler, MD;Robert C.G. Martin II, MD, PhD, FACS
August 20th 2025

Experts discuss how initial postoperative visits after colorectal cancer surgery integrate pathology review, recurrence risk assessment, and timely ctDNA testing to personalize prognosis and guide surveillance, emphasizing the importance of surgical quality indicators and molecular tools in shaping follow-up care.